These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36415112)

  • 1. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
    Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
    J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
    Leow AH; Azmi AN; Loke MF; Vadivelu J; Graham DY; Goh KL
    J Dig Dis; 2018 Nov; 19(11):674-677. PubMed ID: 30307122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X; Tan P; Song L; Lu Z
    Am J Ther; 2016; 23(6):e1436-e1441. PubMed ID: 25923229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized sequential therapy
    Seddik H; Benass J; Berrag S; Sair A; Berraida R; Boutallaka H
    World J Gastroenterol; 2024 Feb; 30(6):556-564. PubMed ID: 38463026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
    Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
    Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.
    Ding YM; Duan M; Han ZX; Song XH; Zhang FL; Wang Z; Ning Z; Zeng SY; Kong QZ; Zhang WL; Liu J; Wan M; Lin MJ; Lin BS; Nan XP; Wang H; Li YY; Zuo XL; Li YQ
    Dig Dis Sci; 2024 Jul; 69(7):2540-2547. PubMed ID: 38700630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadruple therapy for eradication of Helicobacter pylori.
    Ma HJ; Wang JL
    World J Gastroenterol; 2013 Feb; 19(6):931-5. PubMed ID: 23429422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
    Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
    J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
    Song Z; Suo B; Zhang L; Zhou L
    Helicobacter; 2016 Dec; 21(6):462-470. PubMed ID: 27060292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
    Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
    Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Ding YM; Zhang QM; Li RL; Han ZX; Zhao Q; Xu LD; Wang KY; Nan XP; Duan M; Zeng SY; Kong QZ; Wang H; Wu XQ; Zhang N; Li YQ; Zuo XL; Li YY
    Helicobacter; 2024; 29(4):e13121. PubMed ID: 39097924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.